AMENDMENTS TO THE CLAIMS:

Please replace the claims with the claims provided in the listing below wherein status, amendments, additions and cancellations are indicated.

1. (Currently amended) A drug composition comprising [a drug carrier] sucrose and a lecithin-modified superoxide dismutase represented by the following general formula (I) ~~and having following characteristics (a) to (d)~~:

$$SOD' (Q - B)_m \qquad (I)$$

wherein SOD' is a residue of superoxide dismutase; Q is a chemical crosslinking; B is a residue without a hydrogen atom of a hydroxyl group of lysolecithin having the hydroxyl group at the 2-position of glycerol; m is an average number of bonds of lysolecithin to one molecule of superoxide dismutase which is a positive number of 1 or more[[;]].

~~(a) property: when water for injection is added to one which lyophilized the drug composition, the one is dissolved with no insoluble foreign substances;~~

~~(b) stability: when a superoxide dismutase activity per unit weight immediately after lyophilizing the drug composition is set as 100, relative values of the activity after the lyophilized drug composition is stored at 8°C for 12 months, 25°C for 12 months or 40°C for 6 months are all 97% or more;~~

~~(c) peaks of analogues in gel filtration chromatography: when the lyophilized drug composition is re-dissolved and submitted to gel filtration chromatography and absorbance of the eluates is measured at 220 nm, no substantial difference is observed between a peak shape of lecithin-modified superoxide dismutase on a detection chart of the absorbance and a peak shape of lecithin-modified superoxide dismutase before lyophilization; and~~

~~(d) peaks of analogues by reversed phase chromatography: when the lyophilized composition was re-dissolved after it is stored at 8°C for 12 months, 25°C for 12 months or 40°C for 6 months and submitted to reversed phase chromatography and absorbance of the eluates is measured at 220 nm and 270 nm, each amount of detected analogues is not substantially different from that immediately after lyophilized.~~

2. - 3. (Canceled)

4. (Currently amended) The drug composition according to claim 1 ~~or 2~~ wherein a fatty acid content in the drug composition is 0.13-0.15 μmol/mg protein.

5. (Canceled)

6. (Currently amended) The drug composition according claim 1 or [[2]] 4 wherein Q is -C (O) - $(CH_2)_n$-C(O) -, n being an integer of 2 or more.

7. (Currently amended) The drug composition according to claim 1 or [[2]] 4 wherein SOD' is a residue of human superoxide dismutase.

8. (Currently amended) The drug composition according to claim 1 or [[2]] 4 wherein SOD' is a residue of a modified form of superoxide dismutase in which an amino acid in 111-position of an amino acid sequence of human superoxide dismutase is converted into S-(2-hydroxyethylthio) cysteine.

9. (Canceled)

10. (Currently amended) The drug composition according to claim [[6]] 1 or 4 wherein n is an integer of 2 to 10.

11. (Currently amended) The drug composition according to claim 1 or [[2]] 4 wherein m is a positive number of 1 to 12.

12. (Currently amended) The drug composition according to claim [[5]] 1 or 4 wherein the sucrose has been treated with activated charcoal.

13. (Currently amended) The drug composition according to claim 1 or 4 wherein the drug composition is lypholized.

14. (Currently amended) The drug composition according to claim [[5]] 1 or 4 wherein a weight ratio of the lecithin-modified superoxide dismutase to sucrose is 0.4/100–60/100.

15. - 18. (Canceled)